Open Access

Unusual case of pancreatic inflammatory myofibroblastic tumor associated with spontaneous splenic rupture

  • Kamal S Hassan1Email author,
  • Hector I Cohen2,
  • Fadi K Hassan3 and
  • Shadi K Hassan4
World Journal of Emergency Surgery20105:28

DOI: 10.1186/1749-7922-5-28

Received: 5 September 2010

Accepted: 22 November 2010

Published: 22 November 2010

Abstract

Background

Spontaneous splenic rupture considered a relatively rare but life threatening. The three commonest causes of spontaneous splenic rupture are malignant hematological diseases, viral infections and local inflammatory and neoplastic disorders. We describe a unique and unusual case of inflammatory myofibroblastic tumor of the tail of pancreas presented with massively enlarged spleen and spontaneous splenic rupture.

Case presentation

A 19 years old male patient with no significant past medical history presented to emergency room with abdominal pain and fatigue. Massively enlarged spleen was detected. Hypotension and rapid reduction of hemoglobin level necessitated urgent laparatomy. About 1.75 liters of blood were found in abdominal cavity. A large tumor arising from the tail of pancreas and local rupture of an enlarged spleen adjacent to the tumor were detected. Distal pancreatectomy and splenectomy were performed. To our knowledge, we report the first case of massively enlarged spleen that was complicated with spontaneous splenic rupture as a result of splenic congestion due to mechanical obstruction caused by an inflammatory myofibroblastic tumor of the tail of pancreas. A review of the literature is also presented.

Conclusion

Inflammatory myofibroblastic tumor of the tail of pancreas should be included in the differential diagnosis of the etiological causes of massively enlarged spleen and spontaneous splenic rupture.

Introduction

The most common causes of splenomegaly are liver diseases (33%), hematologic malignancies (27%), infections (23%), congestion or inflammation (8%), primary splenic diseases (4%) and others (5%) [1]. Cirrhosis, lymphoma, AIDS and endocarditis, congestive heart failure and splenic vein thrombosis considered the most common causes in each variety - respectively [1]. There are only a few conditions that cause massively enlarged spleen including chronic myeloid leukemia, hairy cell leukemia, lymphoma, myelofibrosis, thalassemia major, visceral leishmaniasis, malaria, tropical splenomegaly syndrome, AIDS with Mycobacterium avium complex and Gaucher disease [2]. Spontaneous splenic rupture considered a relatively rare but life threatening. Recently, Renzulli et al reported a systematic review of 845 cases with spontaneous splenic rupture that had been published over more than 28 years [3]. In 84.1 percent of cases a single etiological factor was found. Two underlying pathologies were found in 8.2 percent of cases and three or more etiological factors were found in 0.7 percent of cases. The three commonest causes of spontaneous splenic rupture were malignant hematological diseases, viral infections and local inflammatory and neoplastic disorders. Massively enlarged spleen and spontaneous splenic rupture caused by inflammatory myofibroblastic tumor (IMT) of the tail of pancreas is unusual and had been not reported before.

Case presentation

Written informed consent was obtained from the patient for publication of this case report. A 19 years old male patient with no significant past medical history presented to emergency room with abdominal pain and fatigue without complains of anorexia, nausea, vomiting, weight loss, jaundice or fever. Physical examination revealed skin pallor, blood pressure 112/72, heart rate 92/min. Abdominal palpation revealed diffuse abdominal tenderness and splenomegaly 22 cm. The liver and regional lymph nodes were not palpable. The remaining physical examination was unremarkable. Computed tomography (CT) scan of the abdomen showed massive splenomegaly and a solid mass with hypodense area in the tail of the pancreas (Figure 1). No liver lesions or abdominal lymphadenopathy were identified. Blood analysis revealed hemoglobin 10.6 gr/dl, white blood cell were 7000/mm3, platelet count 271000/mm3. Other laboratory analysis including potassium, sodium, calcium, magnesium, phosphorus, blood urea nitrogen, creatinine, serum amylase, lipase, and liver chemistry were all within normal range. Five hours later, blood pressure dropped to 86/55 and reduction of hemoglobin level to 5.9 gr/dl was detected. These findings considered indications for urgent explorative laparotomy. Sudden massive bleeding may cause acute hypovolemic shock even without reduction in the hemoglobin level. The patient underwent an urgent explorative laparotomy. About 1.75 liters of blood were found in abdominal cavity. A large tumor arising from the tail of pancreas and local rupture of an enlarged spleen adjacent to the tumor were detected. Distal pancreatectomy and splenectomy were performed. The postoperative course was without any remarkable complications. Macroscopic pathology revealed a cystic mass measuring 8.2×6.5×6.0 cm in the tail of the pancreas and huge spleen measuring 23.5×15.5×6.3 cm (Figure 2). The pancreatic tumor was adhered to the hilar region of the spleen. The wall of the cystic mass was 1.4 cm. Microscopic pathology showed diffuse myofibroblastic proliferation of the wall of the cystic mass with a variable inflammatory component surrounded by pancreatic parenchyma (Figure 3). The patient has been followed for 6 years without any clinical or radiographic evidence of recurrence.
Figure 1

CT scan of the abdomen showed massive splenomegaly and a solid mass with hypodense area in the tail of the pancreas (arrows).

Figure 2

Macroscopic pathology shows huge spleen measuring 23.5 × 15.5 × 6.3 cm and a cystic mass measuring 8.2 × 6.5 × 6.0 cm located in the tail of the pancreas adhered to the hilar region of the spleen (arrows). Microscopically, red pulp congestion and hyperplasia of the white pulp are shown in the left lower corner.

Figure 3

Panoramic view of the IMT showing fibrin and cellular debris (A). The inner part is formed by cellular area adjacent to necrotic and inflammatory material [Intermediate power magnification - Hematoxylin and eosin stain (B)]. The external area of the pancreatic tissue involved by myofibroblastic cells of the IMT [Low power magnification - Hematoxylin and eosin stain (C)].

Discussion

IMT is a histopathologic entity previously known as an inflammatory pseudotumor which was initially reported in 1990 in the pulmonary system [4]. Different names have been used to describe this entity, such as plasma cell granuloma, plasma cell pseudotumor, inflammatory fibroxanthoma, inflammatory pseudotumor and histiocytoma [5]. The histological features vary slightly from site to site, which may, at least in part, be related to differences in the phase of the lesion's development at the time of the detection. Representative features include the presence of a myofibroblastic proliferation and a varying degree of inflammatory infiltrates, mainly consisting of lymphocytes, histiocytes and plasma cells [6]. A number of the clinical and pathological features of IMT suggest the possibility that this lesion is more similar to a neoplasm than an inflammatory lesion [7]. Some investigators argue that IMT may be a true sarcoma and prefer the term inflammatory fibrosarcoma [79]. Whether IMT and inflammatory fibrosarcoma are actually the same tumor or different entities, it is remains controversial. Now, it is generally accepted that IMT is indeed a true neoplasm with a wide spectrum of histopathological behavior, varying from benign lesions to rare aggressive tumors [7]. Recently, inflammatory fibrosarcoma has become included in the spectrum of inflammatory myofibroblastic proliferations [10].

Although IMT occurs more frequently in the pulmonary system but it had been described in a wide variety of other organs [6]. In a clinicopathologic and immunohistochemical study of 84 cases of extrapulmonary IMT, the involved organs were intra-abdominal sites in 49 cases (58.4%), upper respiratory tract in 9 cases (10.7%), genitourinary tract in 8 cases (9.5%), trunk in 8 cases (9.5%), pelvis and retroperitoneum in 4 cases (4.8%), extremities in 3 cases (3.6%), and head and neck in 3 cases (3.6%) [1113]. Furthermore, IMT has also been reported in the orbit [14], salivary glands [15], spleen [1618], liver [19, 20], urinary bladder and soft tissues [20, 21], skin [22], kidneys [23], heart [24] and central nervous system [25].

IMT of the pancreas is rare. Only 27 cases of IMT located in the pancreas have been reported in English literature [5, 6, 2643]. The age distribution of IMT of the pancreas resembled that of in pulmonary system ranging 2.5 to 70 years. IMT equally affects males and females. Commonly, the clinical presentation of IMT of the pancreas is a mass discovered incidentally by imaging investigations for other reasons. The presenting symptoms and signs of pancreatic IMT were abdominal pain (65.4%), unintentional weight loss (42.3%), jaundice (38.5%), palpable abdominal mass (26.9%) and anemia (23.0%). Associated clinical symptoms included fatigue (11.5%), fever (7.5%), anorexia (7.5%), nausea and vomiting (7.5%).

The presenting symptoms of the reported patient were abdominal pain and fatigue as a result of massively enlarged spleen and anemia due to substantial congestion of the spleen resulted from the location of the IMT in the tail of pancreas that cause a considerable obstruction of the blood drainage from the spleen. The abdominal pain and the anemia caused mainly by the huge palpable spleen rather than by the tumor itself. Anorexia, nausea, vomiting, weight loss or jaundice, were not included in the presenting symptoms of our patient. It was reported that one patient with IMT located in the body and the tail of the pancreas developed splenic vein thrombosis resulting in splenomegaly, thrombocytopenia and upper gastrointestinal hemorrhage from isolated gastric varices [31]. The present patient with IMT located in the tail of the pancreas developed massively enlarged spleen as a result of mechanical obstruction caused by the tumor itself and complicated with abdominal bleeding due to spontaneous splenic rupture. No thrombosis of splenic vessles was found and no gastric varices or upper gastrointestinal hemorrhage were detected. Surprisingly, also no thrombocytopenia or leukopenia, were observed.

The tumor was located in the head of the pancreas in 57.7% of cases, whereas it was found in the body and the tail of the pancreas in 42.3%. IMT of the pancreas has a tendency to be a larger in size than that in the pulmonary system at the time of diagnosis ranging 1.5-13 cm [5, 11]. The size of the IMT in the presented patient was 8.2 × 6.5 × 6.0 cm. Almost all patients underwent exploratory laparotomy and surgical resection. However, correct diagnoses were not made in any of these patients including the presented patient before pancreatic resection, even with an intraoperative frozen section biopsy.

Complete surgical resection is the treatment of choice for IMT without any need of chemotherapy and radiation therapy [24, 44, 45]. The prognosis of IMT is generally good, with only a rare incidence of malignant transformation [44]. However, a significant recurrence rate of 25% was reported [11]. IMT of the retroperitoneum has susceptibility for more aggressive behavior with multiple recurrences [44]. It was suggested that the presence of atypia, ganglion-like cells and p53 expression may suggest more aggressive behavior [46, 47]. These lesions may be indistinguishable from inflammatory fibrosarcoma due to a high degree of clinical and morphological overlap [44]. Radiation therapy [9, 48, 49], immunosuppressive therapy [50] and chemotherapy with or without combined radiation therapy [11, 44] had been considered in the management of aggressive IMT or inflammatory fibrosarcoma.

Because of a higher recurrence rate, approaching 25% in extrapulmonary IMT, our patient has been closely followed with no clinical or radiographic evidence of recurrence for 6 years following surgery.

Conclusion

Inflammatory myofibroblastic tumor of the tail of pancreas should be included in the differential diagnosis of the etiological causes of massively enlarged spleen and spontaneous splenic rupture.

Declarations

Authors’ Affiliations

(1)
Clalit Health Services, Ruth and Bruce Rappaport Faculty of Medicine
(2)
Pathology Department, Western Galilee Hospital
(3)
Sackler Faculty of Medicine, Tel Aviv University
(4)
Internal Medicine Department, Carmel Medical Center

References

  1. O'Reilly RA: Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients. West J Med. 1998, 169 (2): 88-97.PubMed CentralPubMedGoogle Scholar
  2. Bedu-Addo G, Bates I: Causes of massive tropical splenomegaly in Ghana. Lancet. 2002, 360 (9331): 449-54. 10.1016/S0140-6736(02)09680-0.PubMedGoogle Scholar
  3. Renzulli P, Hostettler A, Schoepfer AM, Gloor B, Candinas D: Systematic review of atraumatic splenic rupture. Br J Surg. 2009, 96: 1114-1121. 10.1002/bjs.6737.PubMedGoogle Scholar
  4. Pettinato G, Manivel JC, De Rosa N, Dehner LP: Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol. 1990, 94: 538-546.PubMedGoogle Scholar
  5. Yamamoto H, Watanabe K, Nagata M, Tasaki K, Honda I, Watanabe S, Soda H, Takenouti T: Inflammatory myofibroblastic tumor (IMT) of the pancreas. J Hepatobiliary Pancreat Surg. 2002, 9: 116-119. 10.1007/s005340200013.PubMedGoogle Scholar
  6. Dishop MK, Warner BW, Dehner LP, Kriss VM, Greenwood MF, Geil JD, Moscow JA: Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy. J Pediatr Hematol. 2003, 25: 153-158. 10.1097/00043426-200302000-00014.Google Scholar
  7. Coffin CM, Dehner LP, Meis-Kindblom JM: Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Semin Diagn Pathol. 1998, 15: 102-110.PubMedGoogle Scholar
  8. Meis JM, Enzinger FM: Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol. 1991, 15: 1146-1156. 10.1097/00000478-199112000-00005.PubMedGoogle Scholar
  9. Meis-Kindblom JM, Kjellstrom C, Kindblom LG: Inflammatory fibrosarcoma: update, reappraisal, and perspective on its place in the spectrum of inflammatory myofibroblastic tumors. Semin Diagn Pathol. 1998, 15: 133-143.PubMedGoogle Scholar
  10. Walsh SV, Evangelista F, Khettry U: Inflammatory myofibroblastic tumor of the pancreaticobiliary region: morphologic and immunocytochemical study of three cases. Am J Surg Pathol. 1998, 22: 412-418. 10.1097/00000478-199804000-00004.PubMedGoogle Scholar
  11. Wreesmann V, van Eijck CH, Naus DC, van Velthuysen ML, Jeekel J, Mooi WJ: Inflammatory pseudotumour (inflammatory myofibroblastic tumour) of the pancreas: a report of six cases associated with obliterative phlebitis. Histopathology. 2001, 38: 105-110. 10.1046/j.1365-2559.2001.01056.x.PubMedGoogle Scholar
  12. Coffin CM, Watterson J, Priest JR, Dehner LP: Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995, 19: 859-872. 10.1097/00000478-199508000-00001.PubMedGoogle Scholar
  13. Misselevitch I, Podoshin L, Fradis M, Naschitz JE, Yeshurun D, Boss JH: Inflammatory pseudotumor of the neck. Otolaryngol Head Neck Surg. 1991, 105: 864-867.PubMedGoogle Scholar
  14. Wenig BM, Devaney K, Bisceglia M: Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm. Cancer. 1995, 76: 2217-2229. 10.1002/1097-0142(19951201)76:11<2217::AID-CNCR2820761107>3.0.CO;2-N.PubMedGoogle Scholar
  15. Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L: What is orbital pseudotumor?. Surv Ophthalmol. 1996, 41: 66-78. 10.1016/S0039-6257(97)81996-0.PubMedGoogle Scholar
  16. Huang C, Damrose E, Bhuta S, Abemayor E: Kuttner tumor (chronic sclerosing sialadenitis). Am J Otolaryngol. 2002, 23: 394-397. 10.1053/ajot.2002.126855.PubMedGoogle Scholar
  17. Thomas RM, Jaffe ES, Zarate-Osorno A, Medeiros LJ: Inflammatory pseudotumor of the spleen. A clinicopathologic and immunophenotypic study of eight cases. Arch Pathol Lab Med. 1993, 117: 921-926.PubMedGoogle Scholar
  18. Neuhauser TS, Derringer GA, Thompson LD, Fanburg-Smith JC, Aguilera NS, Andriko J, Chu WS, Abbondanzo SL: Splenic inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunophenotypic study of 12 cases. Arch Pathol Lab Med. 2001, 125 (3): 379-385.PubMedGoogle Scholar
  19. Nakanuma Y, Tsuneyama K, Masuda S, Tomioka T: Hepatic inflammatory pseudotumor associated with chronic cholangitis: report of three cases. Hum Pathol. 1994, 25: 86-91. 10.1016/0046-8177(94)90176-7.PubMedGoogle Scholar
  20. Venkataraman S, Semelka RC, Braga L, Danet IM, Woosley JT: Inflammatory myofibroblastic tumor of the hepatobiliary system: report of MR imaging appearance in four patients. Radiology. 2003, 227: 758-763. 10.1148/radiol.2273020572.PubMedGoogle Scholar
  21. Ramachandra S, Hollowood K, Bisceglia M, Fletcher CD: Inflammatory pseudotumor of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases. Histopathology. 1995, 27: 313-323. 10.1111/j.1365-2559.1995.tb01521.x.PubMedGoogle Scholar
  22. Tsuzuki T, Magi-Galluzzi C, Epstein JI: ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol. 2004, 28 (12): 1609-1614. 10.1097/00000478-200412000-00009.PubMedGoogle Scholar
  23. El Shabrawi-Caelen L, Kerl K, Cerroni L, Soyer HP, Kerl H: Cutaneous inflammatory pseudotumor--a spectrum of various diseases?. J Cutan Pathol. 2004, 31 (9): 605-611. 10.1111/j.0303-6987.2004.00239.x.PubMedGoogle Scholar
  24. Kapusta LR, Weiss MA, Ramsay J, Lopez-Beltran A, Srigley JR: Inflammatory myofibroblastic tumors of the kidney: a clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol. 2003, 27 (5): 658-666. 10.1097/00000478-200305000-00009.PubMedGoogle Scholar
  25. de Montpreville VT, Serraf A, Aznag H, Nashashibi N, Planché C, Dulmet E: Fibroma and inflammatory myofibroblastic tumor of the heart. Ann Diagn Pathol. 2001, 5 (6): 335-342. 10.1053/adpa.2001.29340.PubMedGoogle Scholar
  26. Hausler M, Schaade L, Ramaekers VT, Doenges M, Heimann G, Sellhaus B: Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol. 2003, 34 (3): 253-262. 10.1053/hupa.2003.35.PubMedGoogle Scholar
  27. Johnson RL, Page DL, Dean RH: Pseudotumor of the pancreas. South Med J. 1983, 76: 647-649.PubMedGoogle Scholar
  28. Abrebanel P, Sarfaty S, Gal R, Chaimoff C, Kessler E: Plasma cell granuloma of the pancreas. Arch Pathol Lab Med. 1984, 108: 531-532.PubMedGoogle Scholar
  29. Scott L, Blair G, Taylor G, Dimmick J, Fraser G: Inlammatory pseudotumors in children. J Pediatr Surg. 1988, 23: 755-758. 10.1016/S0022-3468(88)80419-6.PubMedGoogle Scholar
  30. Stringer MD, Ramani P, Yeung CK, Capps SN, Kiely EM, Spitz L: Abdominal inflammatory myofibroblastic tumours in children. Br J Surg. 1992, 79: 1357-1360. 10.1002/bjs.1800791239.PubMedGoogle Scholar
  31. Dudiak KM: Inflammatory pseudotumor of the pancreas. AJR Am J Roentgenol. 1993, 160: 1324-1325.PubMedGoogle Scholar
  32. Palazzo JP, Chang CD: Inflammatory pseudotumor of the pancreas. Histopathology. 1993, 23: 475-477. 10.1111/j.1365-2559.1993.tb00498.x.PubMedGoogle Scholar
  33. Uzoaru I, Chou P, Reyes-Mugica M, Shen-Schwarz S: Inflammatory myofibroblastic tumor of the pancreas. Surg Pathol. 1993, 5: 181-188.Google Scholar
  34. Kroft SH, Stryker SJ, Winter JN, Ergun G, Rao MS: Inflammatory pseudotumor of the pancreas. Int J Pancreatol. 1995, 18: 277-283.PubMedGoogle Scholar
  35. Qanadli SD, d'Anthouard F, Cugnec JP, Frija G: Plasma cell granuloma of the pancreas: CT finding. J Comput Assist Tomogr. 1997, 21: 735-736. 10.1097/00004728-199709000-00013.PubMedGoogle Scholar
  36. Shankar KR, Losty PD, Khine MM, Lamont GL, McDowell HP: Pancreatic inflammatory tumour: a rare entity in childhood. J R Coll Surg Edinb. 1998, 43: 422-423.PubMedGoogle Scholar
  37. Petter LM, Martin JK, Menke DM: Localized lymphoplasmacellular pancreatitis forming a pancreatic inflammatory pseudotumor. Mayo Clin Proc. 1998, 73: 447-450. 10.4065/73.5.447.PubMedGoogle Scholar
  38. Morris-Stiff G, Vujanic GM, Al-Wafi A, Lari J: Pancreatic inflammatory pseudotumour: an uncommon childhood lesion mimicking a malignant tumor. Pediatr Surg Int. 1998, 13: 52-54. 10.1007/s003830050243.PubMedGoogle Scholar
  39. McClain MB, Burton EM, Day DS: Pancreatic pseudotumor in an 11-year-old child: imaging findings. Pediatr Radiol. 2000, 30: 610-613. 10.1007/s002470000227.PubMedGoogle Scholar
  40. Liu TH, Consorti ET: Inflammatory pseudotumor presenting as a cystic tumor of the pancreas. Am Surg. 2000, 66: 993-997.PubMedGoogle Scholar
  41. Slavotinek JP, Bourne AJ, Sage MR, Freeman JK: Inflammatory pseudotumour of the pancreas in a child. Pediatr Radiol. 2000, 30: 801-803. 10.1007/s002470000331.PubMedGoogle Scholar
  42. Esposito I, Bergmann F, Penzel R, di Mola FF, Shrikhande S, Büchler MW, Friess H, Otto HF: Oligoclonal T-cell populations in an inflammatory pseudotumor of the pancreas possibly related to autoimmune pancreatitis: an immunohistochemical and molecule analysis. Virchows Archiv. 2004, 444: 119-126. 10.1007/s00428-003-0949-1.PubMedGoogle Scholar
  43. Dagash H, Koh C, Cohen M, Sprigg A, Walker J: Inflammatory myofibroblastic tumor of the pancreas: a case report of 2 pediatric cases - steroid or surgery?. J Pediatr Surg. 2009, 44 (9): 1839-41. 10.1016/j.jpedsurg.2009.06.025.PubMedGoogle Scholar
  44. DiFiore JW, Goldblum JR: Inflammatory myofibroblastic tumor of the small intestine. J Am Coll Surg. 2002, 194: 502-506. 10.1016/S1072-7515(02)01118-3.PubMedGoogle Scholar
  45. Coffin CM: Pseudosarcomatous proliferative lesions. Pediatrics Soft Tissue Tumors. Edited by: Coffin CM, Dehner LP, O'Shea PA. Baltimore, MD, USA: Williams & Wilkins,1997:29-39.Google Scholar
  46. Biselli R, Ferlini C, Fattorossi A: Inflammatory myofibroblastic tumor (inflammatory pseudotumor): DNA flow cytometric analysis of nine pediatric cases. Cancer. 1996, 77: 778-784. 10.1002/(SICI)1097-0142(19960215)77:4<778::AID-CNCR25>3.0.CO;2-X.PubMedGoogle Scholar
  47. Hussong JW, Brown M, Perkins SL: Comparison of DNA ploidy, histoloig and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Mod Pathol. 1999, 12: 279-286.PubMedGoogle Scholar
  48. Imperato JP, Folkman J, Sagerman RH: Treatment of plasma cell granuloma with radiation therapy: a report of two cases and a review of the literature. Cancer. 1986, 57: 2127-2129. 10.1002/1097-0142(19860601)57:11<2127::AID-CNCR2820571107>3.0.CO;2-O.PubMedGoogle Scholar
  49. Tang TT, Segura AD, Oechler HW: Inflammatory myofibrohistiocytic proliferation simulating sarcoma in children. Cancer. 1990, 65: 1626-1634. 10.1002/1097-0142(19900401)65:7<1626::AID-CNCR2820650729>3.0.CO;2-V.PubMedGoogle Scholar
  50. Doski JJ, Priebe CJ, Driessnack M: Corticosteroids in the management of unresected plasma cell granuloma (inflammatory pseudotumor) of the lung. J Pediatr Surg. 1991, 26: 1064-6. 10.1016/0022-3468(91)90674-I.PubMedGoogle Scholar

Copyright

© Hassan et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement